123 related articles for article (PubMed ID: 36892582)
1. The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.
Schober SJ; Schoening C; Eck J; Middendorf C; Lutsch J; Knoch P; von Ofen AJ; Gassmann H; Thiede M; Hauer J; Kolk A; Mantwill K; Gschwend JE; Burdach SEG; Nawroth R; Thiel U; Holm PS
Clin Cancer Res; 2023 May; 29(10):1996-2011. PubMed ID: 36892582
[TBL] [Abstract][Full Text] [Related]
2. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.
Koch J; Schober SJ; Hindupur SV; Schöning C; Klein FG; Mantwill K; Ehrenfeld M; Schillinger U; Hohnecker T; Qi P; Steiger K; Aichler M; Gschwend JE; Nawroth R; Holm PS
Nat Commun; 2022 Aug; 13(1):4689. PubMed ID: 35948546
[TBL] [Abstract][Full Text] [Related]
4. The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.
Klawitter M; El-Ayoubi A; Buch J; Rüttinger J; Ehrenfeld M; Lichtenegger E; Krüger MA; Mantwill K; Koll FJ; Kowarik MC; Holm PS; Naumann U
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077380
[TBL] [Abstract][Full Text] [Related]
5. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
6. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
7. The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer.
Lichtenegger E; Koll F; Haas H; Mantwill K; Janssen KP; Laschinger M; Gschwend J; Steiger K; Black PC; Moskalev I; Nawroth R; Holm PS
Hum Gene Ther; 2019 Jan; 30(1):44-56. PubMed ID: 29916265
[TBL] [Abstract][Full Text] [Related]
8. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
9. YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.
von Ofen AJ; Thiel U; Eck J; Gassmann H; Thiede M; Hauer J; Holm PS; Schober SJ
Front Oncol; 2024; 14():1304374. PubMed ID: 38357194
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
11. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
12. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.
Czolk R; Schwarz N; Koch H; Schötterl S; Wuttke TV; Holm PS; Huber SM; Naumann U
Int J Mol Med; 2019 Oct; 44(4):1484-1494. PubMed ID: 31432139
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
[TBL] [Abstract][Full Text] [Related]
17. Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.
Cheng PH; Rao XM; Duan X; Li XF; Egger ME; McMasters KM; Zhou HS
J Mol Med (Berl); 2015 Feb; 93(2):211-23. PubMed ID: 25376708
[TBL] [Abstract][Full Text] [Related]
18. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
[TBL] [Abstract][Full Text] [Related]
19. Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.
Lv P; Liu X; Chen X; Liu C; Zhang Y; Chu C; Wang J; Wang X; Chen X; Liu G
Nano Lett; 2019 May; 19(5):2993-3001. PubMed ID: 30964695
[TBL] [Abstract][Full Text] [Related]
20. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
